Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous
Reed‐Sternberg cells in an inflammatory background. Patients are commonly diagnosed …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo)
as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma …

PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine,
vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed …

The crude incidence of Hodgkin lymphoma (HL) in the European Union is 2.3, the mortality
0.4 cases/100 000/year. Young adults aged 20–40 years are most often affected. Slightly …

Purpose Patients who receive combined modality treatment for stage I and II Hodgkin
lymphoma (HL) have an excellent outcome. Early response evaluation with positron …

This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with
ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to …

Abstract In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo)
administered in combination were evaluated as initial salvage therapy in patients with …

Radiation therapy (RT) continues to play an important role in the treatment of cancer.
Adaptive RT (ART) is a novel method through which RT treatments are evolving. With the …